1 Indications And Usage Xarelto Is A Factor Xa Inhibitor Indicated: To Reduce Risk Of Stroke And Systemic Embolism In Nonvalvular Atrial Fibrillation ( 1.1 ) For Treatment Of Deep Vein Thrombosis (Dvt) ( 1.2 ) For Treatment Of Pulmonary Embolism (Pe) ( 1.3 ) For Reduction In The Risk Of Recurrence Of Dvt Or Pe ( 1.4 ) For The Prophylaxis Of Dvt, Which May Lead To Pe In Patients Undergoing Knee Or Hip Replacement Surgery ( 1.5 ) For Prophylaxis Of Venous Thromboembolism (Vte) In Acutely Ill Medical Patients ( 1.6 ) To Reduce The Risk Of Major Cardiovascular Events In Patients With Chronic Coronary Artery Disease (Cad) Or Peripheral Artery Disease (Pad) ( 1.7 ) 1.1 Reduction Of Risk Of Stroke And Systemic Embolism In Nonvalvular Atrial Fibrillation Xarelto Is Indicated To Reduce The Risk Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation. There Are Limited Data On The Relative Effectiveness Of Xarelto And Warfarin In Reducing The Risk Of Stroke And Systemic Embolism When Warfarin Therapy Is Well-Controlled [See Clinical Studies (14.1) ]. 1.2 Treatment Of Deep Vein Thrombosis Xarelto Is Indicated For The Treatment Of Deep Vein Thrombosis (Dvt). 1.3 Treatment Of Pulmonary Embolism Xarelto Is Indicated For The Treatment Of Pulmonary Embolism (Pe). 1.4 Reduction In The Risk Of Recurrence Of Deep Vein Thrombosis And/or Pulmonary Embolism Xarelto Is Indicated For The Reduction In The Risk Of Recurrence Of Dvt And/or Pe In Patients At Continued Risk For Recurrent Dvt And/or Pe After Completion Of Initial Treatment Lasting At Least 6 Months. 1.5 Prophylaxis Of Deep Vein Thrombosis Following Hip Or Knee Replacement Surgery Xarelto Is Indicated For The Prophylaxis Of Dvt, Which May Lead To Pe In Patients Undergoing Knee Or Hip Replacement Surgery. 1.6 Prophylaxis Of Venous Thromboembolism In Acutely Ill Medical Patients At Risk For Thromboembolic Complications Not At High Risk Of Bleeding Xarelto Is Indicated For The Prophylaxis Of Venous Thromboembolism (Vte) And Vte Related Death During Hospitalization And Post Hospital Discharge In Adult Patients Admitted For An Acute Medical Illness Who Are At Risk For Thromboembolic Complications Due To Moderate Or Severe Restricted Mobility And Other Risk Factors For Vte And Not At High Risk Of Bleeding [See Warnings And Precautions (5.2) And Clinical Studies (14.1) ]. 1.7 Reduction Of Risk Of Major Cardiovascular Events In Patients With Chronic Coronary Artery Disease (Cad) Or Peripheral Artery Disease (Pad) Xarelto, In Combination With Aspirin, Is Indicated To Reduce The Risk Of Major Cardiovascular Events (Cardiovascular (Cv) Death, Myocardial Infarction (Mi) And Stroke) In Patients With Chronic Coronary Artery Disease (Cad) Or Peripheral Artery Disease (Pad).
|